Rat Proprotein Convertase Subtilisin / Kexin Type 9 (PCSK9) Protein
377€ (20 µg)
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
935106861
info@markelab.com
name
Rat Proprotein Convertase Subtilisin / Kexin Type 9 (PCSK9) Protein
category
Proteins and Peptides
provider
Abbexa
reference
abx694327
tested applications
SDS-PAGE
Description
Proprotein Convertase Subtilisin / Kexin Type 9 (PCSK9) protein is a recombinant Rat protein expressed in HEK293 cells.
Documents del producto
Instrucciones
Data sheet
Product specifications
| Category | Proteins and Peptides |
| Immunogen Target | Proprotein Convertase Subtilisin / Kexin Type 9 (PCSK9) |
| Host | HEK293 cells |
| Assay Type | Activity: Not tested Sequence Fragment: Met1-Gln691 Tag: C-terminal His tag |
| Origin | Rat |
| Observed MW | Calculated MW: 75.9 kDa Observed MW (SDS-PAGE): 60 kDa |
| Expression | Recombinant |
| Purity | >95% (SDS-PAGE) |
| Size 1 | 20 µg |
| Size 2 | 100 µg |
| Size 3 | 500 µg |
| Size 4 | 1 mg |
| Form | Lyophilized |
| Tested Applications | SDS-PAGE |
| Buffer | Prior to lyophilization: PBS, pH 7.4, containing 5% - 8% Trehalose, Mannitol and 0.01% Tween-80. |
| Availability | Shipped within 5-15 working days. |
| Storage | Storage: Store lyophilized between -20 °C and -80°C. Stability: Stable when stored reconstituted at 2-8°C for up to 1 week. Reconstituted aliquots are stable at -20°C for up to 3 months. Shelf Life: 12 months. |
| Dry Ice | No |
| UniProt ID | P59996 |
| Gene ID | 298296 |
| Alias | FH3,PC9,FHCL3,NARC1,LDLCQ1,NARC-1,HCHOLA3 |
| Background | Protein PCSK9 |
| Status | RUO |
| Note | THIS PRODUCT IS FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC, THERAPEUTIC OR COSMETIC PROCEDURES. NOT FOR HUMAN OR ANIMAL CONSUMPTION. Reconstitute in sterile H2O. Do not vortex. |
Descripción
PCSK9 is a serine protease that plays a central role in cholesterol metabolism by regulating the levels of low-density lipoprotein receptors (LDLR) on the cell surface. PCSK9 binds to LDL receptors, promoting their internalization and subsequent degradation in lysosomes, which reduces the uptake of LDL cholesterol (LDL-C) from the bloodstream. Elevated PCSK9 activity leads to hypercholesterolemia and increases the risk of cardiovascular disease due to excessive circulating LDL-C levels. In contrast, loss-of-function mutations in PCSK9 result in reduced LDL receptor degradation, leading to low plasma cholesterol levels and decreased cardiovascular risk. PCSK9 inhibitors, such as monoclonal antibodies (e.g., alirocumab and evolocumab), are highly effective therapies for hypercholesterolemia and cardiovascular disease, as they block PCSK9's activity, preserving LDL receptors on cell surfaces to enhance cholesterol clearance. Beyond lipid metabolism, PCSK9 has been implicated in inflammation, immune regulation, and other pathological processes, making it a versatile target for therapeutic intervention. Its crucial role in cholesterol homeostasis underscores its significance in cardiovascular health and disease management.
Related Products
Guinea pig PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) ELISA Kit
Ver Producto
Human PCSK9 (Proprotein convertase subtilisin/kexin type 9) ELISA Kit
Ver Producto